Thrivent Financial for Lutherans Has $100.71 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Thrivent Financial for Lutherans raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2,759.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 737,772 shares of the company's stock after purchasing an additional 711,970 shares during the quarter. Thrivent Financial for Lutherans owned 0.73% of Neurocrine Biosciences worth $100,705,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Golden State Wealth Management LLC acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $25,000. Brooklyn Investment Group raised its holdings in shares of Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after purchasing an additional 115 shares during the last quarter. Lindbrook Capital LLC lifted its position in shares of Neurocrine Biosciences by 53.5% in the fourth quarter. Lindbrook Capital LLC now owns 373 shares of the company's stock worth $51,000 after purchasing an additional 130 shares in the last quarter. R Squared Ltd acquired a new position in Neurocrine Biosciences during the fourth quarter worth $61,000. Finally, UMB Bank n.a. grew its position in Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company's stock valued at $62,000 after purchasing an additional 309 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NBIX has been the topic of several analyst reports. Guggenheim cut their price target on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating on the stock in a research report on Monday, February 10th. Bank of America reduced their price target on Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft initiated coverage on Neurocrine Biosciences in a research note on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price target for the company. Barclays increased their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an "overweight" rating in a report on Monday, December 23rd. Finally, Canaccord Genuity Group lowered their target price on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $165.24.

Remove Ads

Neurocrine Biosciences Stock Up 1.7 %

Shares of Neurocrine Biosciences stock traded up $1.85 on Friday, hitting $111.92. The stock had a trading volume of 2,315,014 shares, compared to its average volume of 957,981. The stock has a market cap of $11.16 billion, a price-to-earnings ratio of 34.02, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. Neurocrine Biosciences, Inc. has a twelve month low of $105.18 and a twelve month high of $157.98. The business's 50 day moving average is $126.90 and its two-hundred day moving average is $125.15.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. As a group, equities analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences declared that its Board of Directors has authorized a stock buyback plan on Friday, February 21st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

Insider Activity

In other news, CFO Matt Abernethy sold 1,283 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.87, for a total transaction of $196,132.21. Following the transaction, the chief financial officer now directly owns 32,681 shares of the company's stock, valued at approximately $4,995,944.47. This trade represents a 3.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ingrid Delaet sold 272 shares of the business's stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total value of $37,563.20. Following the completion of the sale, the insider now owns 2,507 shares of the company's stock, valued at approximately $346,216.70. This trade represents a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 233,178 shares of company stock valued at $33,906,594. 4.30% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.